Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

References

• DM Parkin, F Bray. The burden of HPV-related cancers. Vaccine. 24(S3): 2006; S11–S25.
   Web of Science ®Google Scholar
• N Muñoz, FX Bosch, X Castellsagué. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International Journal of Cancer. 111(2): 2004; 278–285.
   PubMed Web of Science ®Google Scholar
• G Clifford, S Franceschi, M Diaz. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 24(S3): 2006; S26–S34.
   Web of Science ®Google Scholar
• JS Smith, L Lindsay, B Hoots. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. International Journal of Cancer. 121: 2007; 621–632.
   PubMed Web of Science ®Google Scholar
• L Denny, M Quinn, R Sankaranarayanan. Chapter 8: Screening for cervical cancer in developing countries. Vaccine. 24(S3): 2006; S71–S77.
   Web of Science ®Google Scholar
• SJ Goldie, LK Kuhn, L Denny. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 285: 2001; 3107–3115.
   PubMed Web of Science ®Google Scholar
• SJ Goldie, L Gaffikin, JD Goldhaber-Fiebert. Cost-effectiveness of cervical cancer screening in five developing countries. New England Journal of Medicine. 353(20): 2005; 2158–2168.
   PubMed Web of Science ®Google Scholar
• SJ Goldie, JJ Kim, E Myers. Chapter 19: Cost-effectiveness of cervical cancer screening. Vaccine. 24(S3): 2006; S164–S170.
   Web of Science ®Google Scholar
• R Sankaranarayanan, L Gaffikin, M Jacob. A critical assessment of screening methods for cervical neoplasia. International Journal of Gynaecological Obstetrics. 89(S2): 2005; S4–S12.
   Web of Science ®Google Scholar
• KA Ault, Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 369: 2007; 1861–1868.
   PubMed Web of Science ®Google Scholar
• DM Harper, EL Franco, CM Wheeler. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 367(9518): 2006; 1247–1255.
   PubMed Web of Science ®Google Scholar
• GP Garnett, JJ Kim, K French. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 24(S3): 2006; S178–S186.
   Web of Science ®Google Scholar
• SJ Goldie. Chapter 15: Public health policy and cost-effectiveness analysis. Journal of the National Cancer Institute Monograph. 31: 2003; 102–110.
   Google Scholar
• SJ Goldie, JD Goldhaber-Fiebert, GP Garnett. Chapter 18: Public health policy for cervical cancer prevention: the role of decision science, economic evaluation, and mathematical modeling. Vaccine. 24(S3): 2006; S155–S163.
   Web of Science ®Google Scholar
• JJ Kim, M Brisson, WJ Edmunds. Modeling cervical cancer prevention in developed countries. Vaccine. 26(11): 2008; K76–K86.
   Web of Science ®Google Scholar
• SJ Goldie, JJ Kim, K Kobus. Cost-effectiveness of HPV16,18 vaccination in Brazil. Vaccine. 25(33): 2007; 6257–6270.
   PubMed Web of Science ®Google Scholar
• SJ Goldie, M O’Shea, NG Campos. Health and economic outcomes of HPV16,18 vaccination in 72 GAVI-eligible countries. Vaccine. 26(32): 2008; 4080–4093.
   PubMed Web of Science ®Google Scholar
• SJ Goldie, M Diaz, D Constenla. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Vaccine. 26(S11): 2008; L59–L72.
   Web of Science ®Google Scholar
• Goldie SJ, Diaz M, Kim SY, et al. Mathematical models of cervical cancer prevention in the Asia Pacific region. Vaccine 2008;26(S12):M17-29.
   Google Scholar
• JJ Kim, B Andres-Beck, SJ Goldie. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer. 97(9): 2007; 1322–1328.
   Web of Science ®Google Scholar
• JJ Kim, KE Kobus, M Diaz. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine. 26(32): 2008; 4015–4024.
   PubMed Web of Science ®Google Scholar
• M Diaz, JJ Kim, G Albero. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India. British Journal of Cancer. 99(2): 2008; 230–238.
   Web of Science ®Google Scholar
• SY Kim, SJ Goldie. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics. 26(3): 2008; 191–215.
   PubMed Web of Science ®Google Scholar
• MR Gold, JE Siegel, LB Russell. Cost-effectiveness in Health and Medicine. 1996; Oxford University Press: New York.
   Google Scholar
• World Health Organization. Macroeconomics and Health: investing in health for economic development: report of the commission on macroeconomics and health. 2001; WHO: Geneva.
   Google Scholar
• World Health Organization Statistical Information System. CHOICE (Choosing Interventions that are Cost Effective). At <www.who.int/choice/en/. >. Accessed 29 January 2008.
   Google Scholar
• DB Evans, TT Edejer, T Adam. Methods to assess the costs and health effects of interventions for improving health in developing countries. BMJ. 331(7525): 2005; 1137–1140.
   Web of Science ®Google Scholar
• Disease Control Priorities Project (DCPP). At <www.dcp2.org/main/Home.html. >. Accessed 28 January 2008.
   Google Scholar
• JD Goldhaber-Fiebert, NK Stout, J Ortendahl. Modeling human papillomavirus and cervical cancer for analyses of screening and vaccination. Population Health Metrics. 5(1): 2007; 11.
   Google Scholar
• JJ Kim, KM Kuntz, NK Stout. Multiparameter calibration of a natural history model of cervical cancer. American Journal of Epidemiology. 166(2): 2007; 137–150.
   Web of Science ®Google Scholar
• Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. New England Journal of Medicine 2008;359(8):821-32.
   Google Scholar
• U Kou. Guidelines for estimating costs of introducing new vaccines into the national immunization system. 2002; World Health Organization, Department of Vaccines and Biologicals: Geneva.
   Google Scholar
• World Health Organization. Adding a vaccine to a national immunization programme: decision and implementation. WHO/IVB/05.18. 2005. At: <www.who.int/vaccines-documents/DocsPDF05/777_screen.pdf. >. Accessed 1 August 2008.
   Google Scholar
• JD Goldhaber-Fiebert, SJ Goldie. Estimating the cost of cervical cancer screening in five developing countries. Cost Effectiveness and Resource Allocation. 4: 2006; 13.
   PubMedGoogle Scholar
• International Labour Organization. LABORSTA online database. At: <http://laborsta.ilo.org/. >. Accessed 21 September 2008.
   Google Scholar
• D Hu, SM Bertozzi, E Gakidou. The costs, benefits, and cost-effectiveness of interventions to reduce maternal morbidity and mortality in Mexico. PLoS ONE. 2(1): 2007; e750.
   Web of Science ®Google Scholar
• W Max, DP Rice, HY Sung. Valuing human life: estimating the present value of lifetime earnings, 2000. (October 1, 2004). Center for Tobacco Control Research and Education. Economic Studies and Related Methods. Paper PVLE2000. At: <http://repositories.cdlib.org/ctcre/esarm/PVLE2000/. > Accessed 18 September 2008.
   Google Scholar
• IAVI/PATH. HPV vaccine adoption in developing countries: cost and financing issues. At: <http://www.iavi.org/viewfile.cfm?fid=47496. >. Accessed 29 February 2008.
   Google Scholar
• D Constenla, E Ortega-Barria, RD Rheingans. Economic impact of rotavirus vaccination in Panama. Anales de pediatría (Barcelona). 68(2): 2008; 128–135.
   Google Scholar
• MF Drummond, MJ Sculpher, GW Torrance. Methods for the Economic Evaluation of Health Care Programs. 3rd ed., 2005; Oxford University Press: New York.
   Google Scholar
• SJ Goldie, D Grima, M Kohli. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. International Journal of Cancer. 106(6): 2003; 896–904.
   Web of Science ®Google Scholar
• SY Kim, JA Salomon, SJ Goldie. Economic evaluation of hepatitis B vaccination in low-income countries: using cost-effectiveness affordability curves. Bulletin of World Health Organization. 85(11): 2007; 833–842.
   PubMed Web of Science ®Google Scholar
• World Bank. Regional fact sheet. World Development Indicators 2008: Latin America and the Caribbean. At <http://siteresources.worldbank.org/DATASTATISTICS/Resources/lac_wdi.pdf. >. Accessed 11 September 2008.
   Google Scholar
• JM Agosti, SJ Goldie. Introducing HPV vaccine in developing countries–key challenges and issues. New England Journal of Medicine. 356(19): 2007; 1908–1910.
   PubMed Web of Science ®Google Scholar
• CJ Haug. Human papillomavirus vaccination – reasons for caution. New England Journal of Medicine. 359(8): 2008; 861–862.
   Web of Science ®Google Scholar
• P Musgrove, J Fox-Rushby. Cost-effectiveness analysis for priority setting. Disease Control Priorities in Developing Countries. 2006; 271–283.
   Google Scholar